We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Launches Newest Version of Remisol Advance at AACC

By LabMedica International staff writers
Posted on 01 Aug 2013
Print article
Beckman Coulter, Inc. (Brea, CA, USA) has released the newest, most advanced version of Remisol Advance data management system, v1.7. This software product streamlines laboratory workflow and the management process with improved sample tracking, results archiving, and consolidation of patient test information from multiple instruments in the lab or from multiple labs in the hospital network.

Remisol Advance v1.7 unifies data management by featuring a 166% increase in sample data processing throughput and a 122% increase in sample data storage from the previous version. It helps optimize lab operations by improving results reporting turnaround times, and standardizing laboratory workflow. The new version features increased device connectivity—up to 128 instruments can now be connected to a single server. The lab may connect to Beckman Coulter analyzers as well as selected third-party instruments.

"Remisol Advance v1.7 offers scalability, security, and standardization across the lab enterprise offering benefits such as multisite connectivity, modules to support lab operations and now, third-party connectivity," said Erik Johnson, Beckman Coulter Diagnostics, director, Automation and Informatics Product Management.

Remisol Advance offers an optional Extended Quality Control (EQC) module, which enhances the laboratory quality control process even further, and features intuitive step-by-step creation of protocols.

This new version of Remisol Advance v1.7 was demonstrated at the 2013 AACC annual meeting held in Houston (TX, USA), from July 28–August 1, 2013

Related Links:

Beckman Coulter, Inc.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.